Turning early-stage projects into marketable assets
Universities or research institutes usually release their projects at a stage well before proof-of-concept in animals. At this stage, partnering with industry is either impossible or valuations are still poor. To make the most of these projects, LDC provides appropriate drug discovery know-how and infrastructure required to advance the different projects and yield pharmaceutical leads with strong commercial potential, ready for partnering with industry. Costs incurred by the research institution are calculated on a typical Full Time Employee (FTE) based service pricing model with moderate FTE rates and may – depending on the individual project – be supported by government subsidies. At reasonable costs, partners can thus build substantial value around their projects, continue to contribute during the drug discovery phase and attain a steep value increase for their background IP.
Cooperative, risk-sharing partnership approach
The LDC is committed to a cooperative style of partnership with partners working hand-in-hand to attain optimal results. New IP generated in the course of the drug discovery process will be shared between the LDC and its partners according to the respective intellectual and financial contribution of each party, with the larger part being retained by the partner. Upon successful commercialization, the LDC will thus be able to participate in the upside of jointly created leads.
